Abbott’s Yili Pritchett shares adaptive trial results at SMi’s Adaptive Designs in Clinical Drug Development Conference

Yili Pritchett of Abbott was able to show real data from a trial we ran for them between 2007-2009. She obscured the medical condition under study, otherwise it was a frank and full explanation of all the issues and it was a well-received talk (everyone loves a case study more than purely theoretical presentations).

The trial stopped for futility after 34 automated interim analyses, saving, in her phase, “millions of dollars” and avoiding exposing at least 70 further patients to an unsuccessful treatment. She presented some of the detailed data analyses slides we had prepared for the clinical team and Yili stressed the role of Tessella in making this trial run really smoothly. Despite it being the first adaptive trial Abbott ran, the whole design and set up of the trial (involving our partners Berry Consultants advising on the statistical design, and Tessella implementing a fast track data collection for the key endpoint data) took only 6 months. Many non-adaptive trials take as long to design, and this design saved considerably more than that in time, (as well as in number of subjects and money) by combining proof-of-concept and dose finding in the one trial.